Iluvien

Fluocinolone Acetonide, the active ingredient in Iluvien, is a corticosteroid presented as a 0.19 mg sustained‑release intravitreal implant for intravitreal administration. It is indicated for the treatment of chronic diabetic macular edema and chronic non‑infectious posterior uveitis in patients who have previously received corticosteroid therapy.

GNH USA supplies Iluvien as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support global distribution. Customers benefit from reliable supply chains and responsive technical support.

Iluvien (fluocinolone acetonide) is used to manage ocular inflammatory and vascular conditions that cause retinal fluid accumulation.

- Chronic diabetic macular edema (DME): reduces retinal swelling and helps improve visual acuity in chronic cases previously treated with corticosteroids. - Chronic non‑infectious posterior uveitis: controls intra‑ocular inflammation and prevents recurrence of macular edema. - Persistent retinal edema: provides sustained anti‑inflammatory effect to maintain fluid control and limit disease progression.

Iluvien may cause ocular and systemic reactions after implantation.

Common Side Effects: - Increased intraocular pressure: may require topical therapy. - Cataract formation: especially posterior subcapsular type. - Conjunctival hemorrhage: minor bleeding at injection site. - Vitreous floaters: transient visual disturbances. - Ocular discomfort: mild pain or irritation. - Retinal pigment epithelium changes: observed on imaging.

Serious or Rare Side Effects: - Endophthalmitis: severe intra‑ocular infection requiring urgent treatment. - Persistent elevated intraocular pressure requiring surgical intervention. - Severe cataract necessitating extraction. - Retinal tear or detachment. - Optic nerve damage leading to vision loss. - Systemic glucocorticoid effects (rare).

Prior to Iluvien implantation, clinicians should assess patient suitability and monitor for complications.

- Monitor intraocular pressure: schedule regular IOP checks after implantation. - Assess for cataract development: perform lens examinations periodically. - Avoid in active ocular infection: postpone implantation until infection resolved. - Use with caution in glaucoma patients: consider alternative therapy. - Pregnancy and lactation: safety not established; weigh risks and benefits. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Iluvien may interact with other ocular or systemic therapies.

Major Interactions (Avoid): - Concurrent intraocular corticosteroids: additive risk of intraocular pressure rise. - Systemic immunosuppressants: may increase susceptibility to ocular infection. - Anticoagulant therapy: heightened risk of intraocular hemorrhage during implantation.

Moderate Interactions (Monitor Closely): - Intravitreal anti‑VEGF agents administered within 4 weeks: potential alteration of efficacy. - Topical prostaglandin analogues for glaucoma: may affect IOP control. - Systemic CYP450 inducers: could modestly reduce local steroid exposure.